Inhalation Anesthesia for Animals: Techniques, Equipment, and Drug Effects

Inhalation anaesthetics provide better control of anaesthetic depth than injectable agents.

Advantages:

• Precise adjustments using vaporizers.
• Predictable elimination via the lungs (less accumulation in tissues).
• Better suited for prolonged procedures compared to injectables.

Modern inhalation anaesthetics (e.g., isoflurane, sevoflurane, desflurane) are designed for:

• Fast induction and recovery (low blood-gas solubility).
• Minimal metabolism → Reduces toxicity risks (especially for liver/kidney patients).
• Non-flammable and non-irritating.

Ether was one of the earliest inhalation anaesthetics, but it had major disadvantages:

• Flammability risk, especially in operating rooms using electrocautery.
• Irritation to the airway, causing coughing and secretions.
• Slow induction and recovery, making it impractical for modern use.

MAC (Minimum Alveolar Concentration) is a standardized measure of an inhalation anaesthetic’s potency.

• It indicates the concentration needed to prevent movement in 50% of patients exposed to a noxious stimulus.
• MAC values guide anaesthetic dosing, ensuring the appropriate depth of anaesthesia without excessive side effects.

Other factors (e.g., blood-gas solubility) determine speed of induction and recovery, not MAC itself.

MAC decreases when the body requires less anaesthetic to maintain anaesthesia.

Factors that lower MAC (increase potency):

• Hypothermia → Slows metabolism, reducing anaesthetic requirements.
• Older age → Decreased nervous system activity.
• Opioids, sedatives, and α2-agonists → Potentiate anaesthesia, reducing MAC.

1.0 × MAC (~1.3%) provides light surgical anaesthesia.

1.3 – 1.5 × MAC (~1.7 – 2.0%) is needed for deep surgical anaesthesia.

>2.0 × MAC can cause severe respiratory and cardiovascular depression.

Nitrous oxide has a high MAC (~200%), meaning it is a weak anaesthetic on its own.

When combined with volatile agents, it lowers their MAC:

• Reduces the required dose of isoflurane or sevoflurane.
• Decreases inhalant-induced cardiovascular depression.

Inhalation anaesthetics (e.g., isoflurane, sevoflurane, desflurane) induce unconsciousness but do NOT provide sufficient analgesia.

Once anaesthesia wears off, pain perception returns quickly, making additional pain control necessary.

Multimodal pain management (opioids, NSAIDs, local anaesthetics) is required for surgical patients.

Nitrous oxide (N₂O) blocks NMDA receptors, which are involved in pain perception and central sensitization.

• Provides mild analgesia, but alone is not sufficient for surgical anaesthesia.
• Reduces MAC of other volatile agents, allowing lower doses of isoflurane or sevoflurane.

Blood-gas solubility determines how quickly an anaesthetic equilibrates between the lungs and blood.

• Low blood-gas solubility (e.g., sevoflurane, desflurane) → Faster induction and recovery.
• High blood-gas solubility (e.g., halothane, methoxyflurane) → Slower induction and prolonged recovery.

High cardiac output increases blood flow to peripheral tissues, leading to:

• Slower rise in alveolar concentration.
• Delayed anaesthetic delivery to the brain, prolonging induction.

Low cardiac output leads to faster induction because more anaesthetic remains in the lungs and quickly reaches the brain.

Desflurane has an extremely low blood-gas solubility, meaning it:

• Rapidly equilibrates between the lungs and blood.
• Induces anaesthesia and allows recovery quickly.

Halothane has a high blood-gas solubility, leading to slow induction and prolonged recovery.

Halothane undergoes ~20–30% hepatic metabolism, making it more likely to cause hepatotoxicity (halothane hepatitis).

Other inhalants (e.g., isoflurane, sevoflurane, desflurane) are minimally metabolized (<2%) and primarily eliminated via the lungs.

Most modern inhalants (e.g., isoflurane, sevoflurane, desflurane) are eliminated primarily through exhalation.

Minimal metabolism occurs in the liver or kidneys, reducing organ toxicity.

• Nitrous oxide diffuses rapidly into the lungs after withdrawal of the anesthetic, displacing oxygen and potentially causing hypoxia.
• To prevent diffusion hypoxia, administer 100% oxygen for 5–10 minutes after stopping N₂O.

Older agents like ether and cyclopropane were highly flammable, posing fire hazards in surgical settings.

Modern agents (e.g., isoflurane, sevoflurane, desflurane) are non-flammable, improving safety in electrocautery procedures.

Sevoflurane can degrade in CO₂ absorbents (e.g., soda lime), forming Compound A, which:

• Has been linked to renal toxicity in laboratory studies (rats).
• Its clinical significance in veterinary medicine remains uncertain.

Modern practice recommends using fresh CO₂ absorbents to minimize Compound A formation.

Halothane is metabolized by the liver (~20–30%), leading to the production of reactive metabolites.

Repeated exposure can cause immune-mediated hepatic damage, known as halothane hepatitis.

Modern agents like isoflurane and desflurane have minimal metabolism (<2%), reducing hepatotoxicity risks.

• Methoxyflurane was metabolized (~50%) by the liver, releasing fluoride ions.
• High fluoride levels led to nephrotoxicity, causing polyuria and kidney damage.
• Safer alternatives (e.g., isoflurane, sevoflurane) replaced methoxyflurane.

Sevoflurane reacts with CO₂ absorbents, forming Compound A, which:

• Has been linked to renal toxicity in rats.
• Its clinical relevance in veterinary medicine remains uncertain.

Minimizing exposure to degraded sevoflurane reduces risk.

Isoflurane undergoes minimal metabolism (~0.2%), making it safer for patients with liver or kidney disease.

Halothane (~20–30%) and methoxyflurane (~50%) undergo extensive metabolism, increasing toxicity risks.

Sevoflurane (~3–5%) is also safer than halothane but carries risks due to Compound A formation.

Halothane undergoes hepatic metabolism, forming reactive metabolites.

In some patients, these metabolites trigger an immune-mediated response, causing liver failure.

Symptoms of halothane hepatitis:

• Jaundice
• Elevated liver enzymes (ALT, AST)
• Hepatic necrosis in severe cases

Modern volatile agents (e.g., isoflurane, desflurane) are primarily exhaled unchanged.

Minimal hepatic metabolism (~0.2% for isoflurane, ~0.02% for desflurane) reduces organ toxicity.

Older agents like halothane and methoxyflurane required extensive metabolism, increasing hepatotoxicity and nephrotoxicity risks.

Most inhalation anaesthetics (e.g., isoflurane, sevoflurane, desflurane) cause vasodilation, which leads to:

• Reduced systemic vascular resistance (SVR).
• Dose-dependent hypotension.

Halothane is an exception, as it depresses myocardial contractility rather than causing vasodilation.

Halothane sensitizes the heart to catecholamines (e.g., epinephrine, norepinephrine), increasing the risk of arrhythmias.

This effect is significant in patients with high circulating catecholamines (e.g., stress, surgical stimulation).

Isoflurane, sevoflurane, and desflurane have much lower arrhythmogenic potential.

• All volatile anaesthetics depress the respiratory center in the brainstem, leading to:
  • Reduced tidal volume (shallow breathing).
  • Decreased respiratory rate at high doses.
  • Hypoventilation and increased CO₂ levels (hypercapnia).

  Reduced tidal volume (shallow breathing).

• Sevoflurane and isoflurane cause bronchodilation, which can be beneficial in some cases (e.g., asthmatic patients).

Malignant hyperthermia (MH) is a life-threatening condition triggered by halogenated anaesthetics and depolarizing muscle relaxants.

Halothane is the most potent trigger, followed by isoflurane, sevoflurane, and desflurane.

Signs of MH:

• Hyperthermia
• Muscle rigidity
• Tachycardia
• Metabolic acidosis

Treatment: Dantrolene (muscle relaxant), cooling, and supportive care.

Most volatile anaesthetics cause cerebral vasodilation, leading to:

• Increased cerebral blood flow (CBF).
• Potential increase in intracranial pressure (ICP), which is a concern in brain trauma cases.

Hyperventilation can counteract this effect by lowering CO₂, causing vasoconstriction and reduced ICP.

Nitrous oxide differs from volatile agents because it does NOT cause vasodilation or myocardial depression.

It maintains sympathetic tone, preserving cardiac output and blood pressure.

This makes it useful in hypotensive patients when used in combination with other agents.

All volatile anaesthetics cause dose-dependent respiratory depression by:

• Reducing tidal volume and respiratory rate.
• Leading to CO₂ retention (hypercapnia).

Mechanical ventilation is required in many cases to:

• Maintain adequate oxygenation and prevent hypercapnia.
• Ensure consistent gas exchange and anaesthetic depth.

Most volatile anaesthetics increase cerebral blood flow (CBF), which can raise intracranial pressure (ICP).

This is dangerous in patients with brain tumors or traumatic brain injury, where increased ICP can cause brainstem herniation.

To manage ICP under anaesthesia:

• Hyperventilate the patient to lower CO₂ levels.
• Use agents with minimal cerebral vasodilation.

Opioids are often used in combination with inhalation anaesthetics to enhance anaesthesia and reduce MAC.

Lower MAC reduces cardiovascular depression caused by volatile agents.

Opioids provide analgesia, which most volatile agents lack.

Alpha-2 agonists cause sedation and analgesia by inhibiting norepinephrine release in the CNS.

They reduce MAC, meaning lower doses of volatile agents are required.

Common combinations: Isoflurane + dexmedetomidine → Balanced anaesthesia with lower cardiovascular depression.

Inhalation anaesthetics potentiate neuromuscular blocking drugs, prolonging paralysis.

Lower doses of neuromuscular blockers are required when using inhalation anaesthetics.

Patients must be monitored for prolonged paralysis and assisted ventilation may be necessary.

Halothane increases the sensitivity of the heart to catecholamines (e.g., epinephrine, norepinephrine).

This predisposes patients to ventricular arrhythmias, especially under stress or high circulating catecholamines.

Isoflurane, sevoflurane, and desflurane have a much lower risk of this effect.

• Nitrous oxide inactivates vitamin B12-dependent enzymes, leading to:
• Bone marrow suppression (megaloblastic anemia).
• Neuropathy due to impaired myelin synthesis.
• Risk increases with prolonged exposure in poorly ventilated environments.
• Scavenging systems and adequate ventilation reduce occupational exposure risks.

Long-term exposure to inhalation anaesthetics is associated with:

• Neurological issues (headaches, dizziness, cognitive impairment).
• Reproductive toxicity (increased miscarriage risk and fetal abnormalities).
• Hepatic and renal toxicity, especially with older agents like halothane and methoxyflurane.

Proper scavenging systems and ventilation help minimize risks.

Scavenging systems remove waste anaesthetic gases, preventing accumulation in the workplace.

Other effective measures include:

• Regular maintenance of vaporizers and breathing circuits to prevent leaks.
• Using low fresh gas flows to minimize room contamination.
• Ensuring a good seal with endotracheal tubes.

Hypothermia lowers metabolic activity and CNS excitability, reducing MAC.

This means lower doses of inhalation anaesthetics are required for the same anaesthetic depth.

Conversely, hyperthermia increases MAC, requiring higher concentrations.

N₂O has a high MAC, but when combined with other inhalants, it reduces the required dose of volatile agents (e.g., isoflurane, sevoflurane).

This results in fewer cardiovascular and respiratory side effects.

N₂O diffuses rapidly into air-filled spaces due to its low blood solubility.

This leads to expansion of pneumothorax, GDV, or bowel distension.

Xenon has excellent pharmacokinetics with minimal metabolism, making it ideal for fast recovery.

However, its high cost limits its veterinary use.

Ether was one of the earliest inhalation anaesthetics but had major disadvantages:

• High flammability, making it dangerous in operating rooms.
• Irritation to the airway, causing coughing and excessive secretions.

Halothane increases sensitivity to catecholamines, increasing the risk of ventricular arrhythmias.

It also has hepatotoxicity risks (halothane hepatitis), limiting its use.

Methoxyflurane was metabolized (~50%) by the liver, producing fluoride ions that were nephrotoxic.

This led to polyuria, renal failure, and severe nephrotoxicity, causing its discontinuation.

Modern inhalants (e.g., isoflurane, sevoflurane) have minimal metabolism and are safer.

Sevoflurane is less irritating to airways than isoflurane and desflurane, making it preferred for mask induction.

It has a low blood-gas solubility, leading to rapid induction and recovery.

The second gas effect occurs when a rapidly absorbed gas (e.g., nitrous oxide) pulls another inhalation anaesthetic into the bloodstream faster.

This enhances the uptake of agents like isoflurane or sevoflurane, speeding up induction.

It does NOT directly reduce MAC, though it allows lower concentrations of other gases to be used.

Isoflurane is widely used due to its:

• Minimal metabolism (~0.2%), reducing toxicity risks.
• Stable cardiovascular effects, though it can cause hypotension via vasodilation.

Halothane is rarely used due to hepatotoxicity risks, and desflurane requires a specialized vaporizer.

Desflurane has a much lower blood-gas solubility (~0.42) than isoflurane (~1.4), making its induction and recovery much faster.

This allows for better control of anaesthetic depth and quicker patient wake-up after surgery.

Desflurane requires a heated vaporizer due to its high volatility, whereas isoflurane does not.

Sevoflurane has a very low blood-gas solubility coefficient (~0.69), leading to rapid induction and recovery.

It is often preferred in small animal and exotic medicine due to its smooth recoveries.

Sevoflurane reacts with CO₂ absorbents (e.g., soda lime), producing Compound A, which:

• Has been linked to nephrotoxicity in rats.
• Its clinical significance in veterinary medicine remains uncertain.

To reduce this risk, fresh CO₂ absorbents should be used when administering sevoflurane.

N₂O has a very high MAC (~200%), meaning it requires extremely high concentrations to induce anaesthesia.

It is used as an adjunct to volatile anaesthetics to reduce MAC and improve analgesia.

Enflurane caused seizure-like EEG activity, especially at high doses or during hypocapnia.

Due to this risk, isoflurane largely replaced enflurane in veterinary practice.

Desflurane undergoes the least hepatic metabolism (~0.02%), making it the safest choice for patients with liver disease.

Halothane has the highest metabolism (~20-30%), increasing hepatotoxicity risks.

Sevoflurane can degrade in CO₂ absorbents, forming Compound A, which has been linked to nephrotoxicity in rats.

Its clinical significance in veterinary medicine remains uncertain.

Desflurane has the lowest blood-gas solubility (~0.42), resulting in very fast induction and recovery.

It requires a specialized heated vaporizer due to its high volatility.

Desflurane’s low blood-gas solubility (~0.42) leads to rapid equilibration between the lungs and blood, allowing fast changes in anaesthetic depth.

This makes it ideal for procedures requiring tight control over anaesthesia levels.

It also facilitates quick recovery, reducing post-operative sedation.

Sevoflurane causes minimal airway irritation, making it ideal for mask induction.

Isoflurane and desflurane can cause coughing or laryngospasm due to airway irritation.

Isoflurane causes minimal direct myocardial depression but does induce vasodilation → Mild hypotension.

It is preferred in patients with cardiac disease because it maintains better hemodynamic stability than halothane.

Halothane undergoes ~20-30% hepatic metabolism, increasing the risk of hepatotoxicity (halothane hepatitis).

Modern inhalants like isoflurane and desflurane have minimal metabolism (<0.5%), reducing liver toxicity.

Desflurane has a very low blood-gas solubility (~0.42), allowing it to be eliminated quickly from the lungs once administration stops.

This leads to fast recovery, making it ideal for short procedures where patients need to wake up quickly.

Sevoflurane also provides rapid recovery but is slightly slower than desflurane.

Desflurane has a very low boiling point (~23°C), meaning it evaporates too quickly at room temperature.

A heated vaporizer ensures consistent vaporization and accurate delivery.

Isoflurane undergoes minimal hepatic metabolism (~0.2%), reducing toxicity risks.

Halothane (~20-30% metabolism) has a high risk of hepatotoxicity and sensitization to catecholamines.

MAC (Minimum Alveolar Concentration) represents the concentration at which 50% of patients do not respond to a noxious stimulus.

For surgical anaesthesia, a multiple of 1.3 – 1.5 × MAC is typically required to ensure sufficient depth of anaesthesia.

Lower MAC multiples (e.g., 1.0 × MAC) provide only light anaesthesia, while higher multiples (e.g., >2.0 × MAC) increase the risk of cardiovascular and respiratory depression.